ARWR vs MDGL
ARWR: Arrowhead Pharmaceuticals is a clinical-stage biotechnology company leveraging its proprietary RNA interference (RNAi) platform to develop potent medicines that silence disease-causing genes. MDGL: Madrigal Pharmaceuticals is a biopharmaceutical company commercializing Rezdiffra, the first and only FDA-approved therapy for adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
Side-by-side fundamentals
| Metric | ARWR | MDGL | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $87.65 | $510.04 | |
| Market cap as of 2026-08-09 | $12.4B | $11.8B | |
| PEG as of 2026-08-09 | -0.49 | -139.05 | MDGL lower |
| Net margin as of 2026-08-09 | -48.4% | -25.3% | MDGL higher |
| Gross margin as of 2026-08-09 | +100.0% | +91.5% | ARWR higher |
| Operating margin as of 2026-08-09 | -35.7% | -25.3% | MDGL higher |
| ROE as of 2026-08-09 | -55.5% | -56.6% | ARWR higher |
| ROA as of 2026-08-09 | -18.1% | -25.5% | ARWR higher |
| Debt / equity as of 2026-08-09 | 2.06 | 0.65 | MDGL lower |
| Revenue growth (YoY) as of 2026-08-09 | +14.1% | +149.0% | MDGL higher |
| Revenue CAGR (3y) SEC XBRL | +50.5% | n/a | |
| Beta as of 2026-08-09 | 1.27 | -1.13 | |
| 1-year return as of 2026-08-07 close | +445.8% | +49.0% | ARWR higher |
Fundamentals: market data, as of 2026-08-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.